Revance Continues To Expect 2024 Total Net Product Revenue, Which Includes Sales Of DAXXIFY And RHA Collection, To Be At Least $280M
Portfolio Pulse from Benzinga Newsdesk
Revance projects its 2024 total net product revenue, including sales from DAXXIFY and RHA Collection, to be at least $280M. With $277.1M in cash and equivalents as of March 31, 2024, and expected revenues and expenditures, the company anticipates reaching cash flow break-even and positive Adjusted EBITDA in 2025.
May 09, 2024 | 8:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Revance anticipates 2024 net product revenue of at least $280M from DAXXIFY and RHA Collection, with a financial outlook reaching cash flow break-even and positive Adjusted EBITDA by 2025.
The positive revenue forecast for 2024 and the company's strong cash position as of March 31, 2024, suggest a solid financial outlook. This, combined with the anticipation of reaching cash flow break-even and positive Adjusted EBITDA by 2025, indicates a positive short-term impact on RVNC's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100